VIA
EWTX icon

Virtus Investment Advisers’s Edgewise Therapeutics EWTX Stock Holding History

Virtus Investment Advisers’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$382K Sell
9,395
-2,149
-19% -$74.1K 0.09% 308
2026
Q1 		$364K Buy
11,544
+281
+2% +$8.1K 0.1% 254
2025
Q4 		$279K Buy
11,263
+3,883
+53% +$77.9K 0.08% 272
2025
Q3 		$120K Buy
7,380
+1,282
+21% +$18.2K 0.03% 405
2025
Q2 		$79.9K Buy
6,098
+269
+5% +$3.88K 0.03% 423
2025
Q1 		$128K Buy
+5,829
New +$153K 0.03% 379

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtus Investment Advisers's EWTX Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Edgewise Therapeutics (EWTX) stake by 19% in Q2 2026, selling an estimated $74.1K and leaving 9,395 shares worth $382K. The position accounts for 0.09% of the portfolio, ranked #308.

Virtus Investment Advisers first reported a position in EWTX in Q1 2025 and has held it in 6 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Virtus Investment Advisers held 9,395 shares of Edgewise Therapeutics worth $382K as of Q2 2026.
  • Virtus Investment Advisers sold 2,149 Edgewise Therapeutics shares in Q2 2026, an estimated $74.1K.
  • Edgewise Therapeutics made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #308 holding.
  • Virtus Investment Advisers first reported a position in Edgewise Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.